article thumbnail

Rilzabrutinib Cuts Flares in IgG4-Related Disease; Fast Track Granted in US

The Pharma Data

The results come from a open-label, proof-of-concept, Phase 2 study (NCT04520451) and highlight rilzabrutinib’s potential as a disease-changing treatment option for a condition that currently has limited and non-specific treatment options and involves substantial patient suffering due to its chronic and progressive course.

Disease 40
article thumbnail

A spatial approach to understanding drug dynamics using mass spectrometry imaging

Drug Target Review

Multiomics MSI studies provide crucial insights into drug pharmacology and toxicity, supporting the development of innovative therapies including chimeric antigen receptor (CAR) T-cell treatments, oligonucleotide therapeutics, antibody drug conjugates (ADCs) and ribonucleic acid (RNA) therapeutics. Bioanalysis 2019, 11 (11), 1099–1116.

Drugs 52
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Nobel Prize celebrates AI’s role in protein structure innovation

Drug Target Review

Baker’s model could revolutionise drug development, synthetic biology, and nanotechnology, opening possibilities for new medical treatments, vaccines, nanomaterials, and sensors. The Rosetta algorithm has been incorporated into AI-powered tools like RoseTTAfold, which uses a three-track neural network to predict protein structures.

article thumbnail

A transatlantic collaboration is uncovering the role of key genetic variants in common diseases like type 2 diabetes and obesity

Broad Institute

Kasper Lage, a Danish-born researcher at Broad, and Niels-Henrik von Holstein-Rathlou, then senior vice president, biomedicine and health sciences, at the Novo Nordisk Foundation (NNF), began chatting in 2019 about the state of the research ecosystem in Denmark and recent scientific advances at Broad.

Disease 72
article thumbnail

Elacestrant 

New Drug Approvals

Randomization was stratified based on whether the ESR1 mutation was detected or not, prior treatment with fulvestrant, and presence of visceral metastasis. [2] Randomization was stratified based on whether the ESR1 mutation was detected or not, prior treatment with fulvestrant, and presence of visceral metastasis. [2] 10,385,008 B2).

FDA 62
article thumbnail

Gepirone

New Drug Approvals

4] It was approved for the treatment of major depressive disorder in the United States in September 2023. [4] 4] It was approved for the treatment of major depressive disorder in the United States in September 2023. [4] 4] It was approved for the treatment of major depressive disorder in the United States in September 2023. [4]

FDA 62
article thumbnail

Tofersen

New Drug Approvals

Tofersen , sold under the brand name Qalsody , is a medication used for the treatment of amyotrophic lateral sclerosis (ALS). [3] Jump up to: a b c d e f g h i j k l “FDA approves treatment of amyotrophic lateral sclerosis associated with a mutation in the SOD1 gene” (Press release). Liu A (1 May 2019). 3 June 2024.